Genomic test predicts chemotherapy resistance in cancer patients

A new genomic test can predict which cancer patients will not respond to common chemotherapy drugs, potentially sparing them from ineffective treatment. The test, developed by researchers at the Spanish National Cancer Research Centre (CNIO) and others, identifies biomarkers indicating resistance to platinum-, taxane-, and anthracycline-based chemotherapies. The test analyzes chromosomal instability patterns in tumors. The research, published in Nature Genetics, used data from over 800 patients with various cancers. Further validation in a hospital setting is planned, with the goal of clinical trials by 2026.